Anbio Biotechnology (NNNN) vs Intellia Therapeutics (NTLA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Intellia Therapeutics (NTLA) has outperformed Anbio Biotechnology (NNNN) over the past year, losing 42.7% versus a loss of 83.4%. Intellia Therapeutics is the larger company by market cap ($1.77 billion vs $202.8 million), about 8.7 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NNNN | NTLA |
|---|---|---|
| Share price | $4.62 | $12.60 |
| Market cap | $202.78M | $1.77B |
| 1-day change | -5.71% | +7.60% |
| YTD return | -83.70% | +30.26% |
| 1-year return | -83.37% | -42.71% |
| 5-year return | — | -91.03% |
| P/E ratio (TTM) | 30.80 | — |
| EPS (TTM) | $0.15 | $-3.35 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $44.73 | $28.25 |
| 52-week low | $4.55 | $7.95 |
| Distance from 52-week high | -89.67% | -55.40% |
| Analyst consensus | — | buy |
| Avg. price target upside | — | +83.41% |
| Average volume | 147.21K | 4.16M |
| Shares outstanding | 43.89M | 140.13M |
| Employees | 27 | 377 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Intellia Therapeutics is about 8.7 times larger than Anbio Biotechnology by market value ($1.77B vs $202.78M).
- NTLA has outperformed NNNN by 40.7 percentage points over the past year.
About Anbio Biotechnology
NNNN stock →Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, and internationally. The company offers lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification, SHA dry chemistry, chemiluminescence immunoassay, and real-time polymerase chain reaction solutions; and SARS-CoV-2 and SARS-CoV-2/Flu A/Flu B antigen rapid test kits.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 27 employees
About Intellia Therapeutics
NTLA stock →Intellia Therapeutics, Inc. operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 377 employees
NNNN vs NTLA FAQ
Which is bigger, Anbio Biotechnology or Intellia Therapeutics?
Intellia Therapeutics (NTLA) is larger, with a market capitalization of $1.77B compared with $202.78M for Anbio Biotechnology (NNNN).
Which stock has performed better over the past year, NNNN or NTLA?
NTLA returned -42.71% over the past 12 months, compared with -83.37% for NNNN (price return, excluding dividends). Past performance does not predict future results.
Are Anbio Biotechnology and Intellia Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry within the Health Care sector.